Content Reviewed By

Reviewed by a board-certified physician (Medical) · Reviewed by a licensed attorney specializing in mass tort litigation (Legal)

Dupixent Safety Concerns

Residents in can register for updates about safety monitoring related to Dupixent use and cancer diagnoses.

Safety Monitoring in , Delaware

Monitoring includes questions about long-term IL-4/IL-13 pathway inhibition, malignancy risk signals, and whether broader legal action develops.

Delaware Deadline Overview

SOL: 2 years
Rule Type: discovery
View Delaware details

Delaware Attorney General — Consumer Protection

In addition to pursuing a civil lawsuit, residents who experienced harm may file a consumer complaint with the Delaware Attorney General's office:

Kathy Jennings, Delaware Attorney General
Consumer Hotline: 1-302-577-8600
Consumer Protection Page →

Filing a consumer complaint creates a public record and may support investigations into manufacturers. Pursuing both channels — AG complaint and civil lawsuit — is recommended.

Federal Court Districts — Delaware

Delaware is served by the following federal judicial district(s). Most Dupixent side effects cases are consolidated in a national MDL, but understanding your local district is useful context:

District of Delaware

⚖️ Filing Deadline Note: Dupixent (dupilumab) side effect claims are an emerging litigation area. The discovery rule clock typically starts when a provider linked your condition — such as eosinophilic esophagitis, alopecia, or other serious effects — to Dupixent use.